ANT-GROUP
Restaurant Brands International Inc. ("RBI"), one of the world's largest quick service restaurant companies and the owner of TIM HORTONS® , BURGER KING® , and POPEYES® brands, today announced a regional partnership to leverage Ant Group’s digital solutions to accelerate digital transformation of its restaurant operations across Asia Pacific. This deal further complements RBI’s continuous efforts to support local franchisee operations and expansion in the Asia Pacific market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005104/en/
Under the collaboration, Ant Group will work with RBI’s local franchisees to implement a range of digital solutions, including mini program Software-as-a-Service (SaaS) solution and Alipay+, a suite of global cross-border mobile payments and marketing solutions. The collaboration aims to enable a more convenient and seamless omni-channel experience for local diners and to uplift the restaurants’ operational efficiency.
With the mini program SaaS solution, Ant Group will develop mini programs for each of RBI’s brands, namely Tim Hortons, Burger King, and Popeyes, adapted for each local market. Via the mini program, RBI’s local franchisees will be able to digitally integrate online and offline operations to drive increased efficiency and gain deeper operational insights. At the same time, diners will have access to expanded services, such as contactless menus and payments, online ordering for pickup or delivery, scan-and-order function in store, etc. Furthermore, the mini programs will also incorporate each RBI brand’s existing loyalty program and provide additional digital marketing capabilities, such as distribution of digital vouchers, etc.
To help RBI’s local restaurants to reach more local diners, the mini programs will be integrated into other local and regional digital platforms, including leading regional F&B tech startup Chope, and e-wallets in Southeast Asia, etc.
The collaboration will also see RBI leveraging the Alipay+ solutions to allow more payment options to be accepted in-store, on websites, apps, and via the mini programs. With the integration of Alipay+ solutions, RBI’s operations will support payment options such as Touch ‘n Go eWallet in Malaysia, True Money wallet in Thailand, GCash in the Philippines, Kakao Pay in South Korea, and many others.
“We couldn’t be more excited to launch this groundbreaking partnership with Ant Group, which further supports our mission to make ordering and dining as easy as possible for our guests and leveraging payments to provide a more convenient and personalized experience,” said Ekrem Ozer, President of APAC, Restaurant Brands International. “Franchisees across Asia will soon be able to benefit from the advantages of digitization across operations and the mini programs’ integration into other digital platforms.”
"Leveraging digital payments and marketing innovations is critical for industries like food and beverage to provide contactless services, boost operational efficiency, and adapt to the fast-changing market conditions,” said Angel Zhao, President of Ant Group’s International Business Group. “We look forward to assisting RBI in its overall digital transformation journey as it reinvents how diners connect with RBI brands both online and offline to create superior customer experiences.”
This activation will take place across eight selected markets in Asia Pacific, and 1,500 restaurants across all three RBI brands.
About Restaurant Brands International Inc.
Restaurant Brands International Inc. is one of the world's largest quick service restaurant companies with approximately $34 billion in annual system-wide sales and over 27,000 restaurants in more than 100 countries. RBI owns three of the world's most prominent and iconic quick service restaurant brands – TIM HORTONS®, BURGER KING®, and POPEYES®. These independently operated brands have been serving their respective guests, franchisees and communities for over 45 years.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
Ant Group is the owner and operator of Alipay, the leading digital payment platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that enable global e-wallets and merchant partners, especially small and medium-sized businesses, to better serve their users and customers from all over the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom